Please wait while the formulary information is being retrieved.
TABLOID (thioguanine)
- acute myeloid leukemia
40 mg tablet
- 2 mg/kg calculated to nearest 20 mg by oral route once daily
Acute myeloid leukemia
- 2 mg/kg calculated to nearest 20 mg by oral route once daily
- 2 mg/kg calculated to nearest 20 mg by oral route once daily for5 days
- 2 mg/kg calculated to nearest 20 mg by oral route once daily for7 days
- 1 mg/kg calculated to nearest 20 mg by oral route 2 times per day
- 1 mg/kg calculated to nearest 20 mg by oral route 2 times per day for 5 days
- 1 mg/kg calculated to nearest 20 mg by oral route 2 times per day for 7 days
- 3 mg/kg calculated to nearest 20 mg by oral route once daily
- 3 mg/kg calculated to nearest 20 mg by oral route once daily for5 days
- 3 mg/kg calculated to nearest 20 mg by oral route once daily for7 days
- 1.5 mg/kg calculated to nearest 20 mg by oral route 2 times per day
- 1.5 mg/kg calculated to nearest 20 mg by oral route 2 times per day for 5 days
- 1.5 mg/kg calculated to nearest 20 mg by oral route 2 times per day for 7 days
- 75 mg/m2 calculated to nearest 20 mg by oral route once daily
- 75 mg/m2 calculated to nearest 20 mg by oral route once daily for 5 days
- 75 mg/m2 calculated to nearest 20 mg by oral route once daily for 7 days
- 37.5 mg/m2 calculated to nearest 20 mg by oral route 2 times perday
- 37.5 mg/m2 calculated to nearest 20 mg by oral route 2 times perday for 5 days
- 37.5 mg/m2 calculated to nearest 20 mg by oral route 2 times perday for 7 days
- 200 mg/m2 calculated to nearest 20 mg by oral route once daily
- 200 mg/m2 calculated to nearest 20 mg by oral route once daily for 5 days
- 200 mg/m2 calculated to nearest 20 mg by oral route once daily for 7 days
- 100 mg/m2 calculated to nearest 20 mg by oral route 2 times per day
- 100 mg/m2 calculated to nearest 20 mg by oral route 2 times per day for 5 days
- 100 mg/m2 calculated to nearest 20 mg by oral route 2 times per day for 7 days
- 0.2 mg/kg calculated to nearest 20 mg by oral route once daily
- 0.2 mg/kg calculated to nearest 20 mg by oral route once daily for 5 days
- 0.2 mg/kg calculated to nearest 20 mg by oral route once daily for 7 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- busulfan
- Myleran
- Abnormal hepatic function tests
- Disease of liver
- Drug-induced hepatitis
- Hepatic veno-occlusive disease
- Hyperbilirubinemia
- Lactation
- Severe infection
Contraindicated
- Anemia
- Bone marrow depression
- Hemorrhage
- Hyperuricemia
- Leukopenia
- Neutropenic disorder
- NUDt15 poor metabolizer
- Pregnancy
- Thrombocytopenic disorder
- TPMT intermediate metabolizer
- TPMT poor metabolizer
Severe
Moderate
- None
TABLOID (thioguanine)
- acute myeloid leukemia
- Anemia
- Immunosuppression
- Infection
- Leukopenia
- Thrombocytopenic disorder
- None
More Frequent
Severe
Less Severe
- Tumor lysis syndrome
- Unsteady gait
- Uric acid nephropathy
- Anorexia
- Diarrhea
- Nausea
- Pruritus of skin
- Skin rash
- Stomatitis
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Focal nodular hyperplasia of liver
- Gastrointestinal perforation
- Gastrointestinal ulcer
- Hepatic necrosis
- Hepatic veno-occlusive disease
- Hepatitis
- Hyperbilirubinemia
- Jaundice
- Peliosis hepatis
- Periportal fibrosis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Thioguanine
- Severity Level:
D
- Additional Notes: Based on animal data, fetal harm may occur
Contraindicated
Thioguanine
Use not recommended, potential tumorigenicity
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Use not recommended, potential tumorigenicity |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Thioguanine
May need to reduce dose.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool